

**PSMB8 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP14577a****Specification**

---

**PSMB8 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [P28062](#)**PSMB8 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 5696**Other Names**

Proteasome subunit beta type-8, Low molecular mass protein 7, Macropain subunit C13, Multicatalytic endopeptidase complex subunit C13, Proteasome component C13, Proteasome subunit beta-5i, Really interesting new gene 10 protein, PSMB8, LMP7, PSMB5i, RING10, Y2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PSMB8 Antibody (N-term) Blocking Peptide - Protein Information****Name** PSMB8**Synonyms** LMP7, PSMB5i, RING10, Y2**Function**

The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Involved in the generation of spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein (PubMed: [27049119](http://www.uniprot.org/citations/27049119)). Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.

**Cellular Location**

Cytoplasm {ECO:0000255|PROSITE-ProRule:PRU00809}. Nucleus

### **PSMB8 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **PSMB8 Antibody (N-term) Blocking Peptide - Images**

### **PSMB8 Antibody (N-term) Blocking Peptide - Background**

The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.

### **PSMB8 Antibody (N-term) Blocking Peptide - References**

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Bravo, M.J., et al. Hum. Immunol. 71(7):708-711(2010) Shi, C., et al. Epidemiol. Infect., 1-9 (2010) In press :Schuurhof, A., et al. Pediatr. Pulmonol. 45(6):608-613(2010) Ustrell, V., et al. FEBS Lett. 376(3):155-158(1995)